Millennium Pharmaceuticals Inc Watch

from 8-K 5 pages Amendment to Letter Agreement

from 8-K 6 pages Amendment to Letter Agreement

from 8-K 5 pages Amendment to Letter Agreement

from 8-K 6 pages Amendment to Letter Agreement

from 8-K 7 pages Amendment to Letter Agreement

from 10-K 10 pages Indemnification Agreement

from 10-K 5 pages Material contract

from 10-K 4 pages Material contract

from 10-K 4 pages June 11, 1999 Joseph B. Bolen, PH.D. 15 Hallview Drive Simsbury, Ct 06070 Dear Joe, on Behalf of Millennium Pharmaceuticals, Inc. (The "Company"), I Am Pleased to Offer You the Position of Vice President, Oncology in the Research Group Reporting to Bob Tepper, Chief Scientific Officer. 1. Job Responsibilities: Your Job Responsibilities in This Position Will Include the Following

from 10-K 4 pages [Millennium Logo] Millennium Pharmaceuticals, Inc

from 10-K 4 pages Millennium Pharmaceuticals, Inc. 2007 Incentive Plan Restricted Stock Unit Agreement

from 10-Q 1 page Material contract

from 10-Q 1 page Material contract

from 10-K 4 pages December 14, 2006 Robert I. Tepper C/O Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Ma 02139 Dear Dr. Tepper

from 10-K 1 page Millennium Pharmaceuticals, Inc. Description of Success Sharing Bonus Program

from 10-K ~10 pages Millennium Pharmaceuticals, Inc. Description of Non-Employee Director Compensation

from 10-K 106 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. Co-Promotion Agreement by and Between Millennium Pharmaceuticals, Inc. and Ortho Biotech Inc. Dated: October 25, 2006

from 10-Q/A 5 pages Amendment No. 1 to Collaboration, Distribution and License Agreement

from 8-K 3 pages [Remainder of Page Intentionally Left Blank]

from 8-K 3 pages Following Our Discussions and Negotiations, This Letter Is Written to Set Out Our Mutual Agreement Pursuant to Section 8.1(a) of the Support Agreement That the Support Agreement Will Terminate and Be of No Further Force or Effect, Effective at 12:01 A.M. (Vancouver Time) Today (Other Than Section 7.4 of the Support Agreement Which Remains in Full Force and Effect). We Acknowledge Anormed Will Be Entering Into a Support Agreement With Genzyme Corporation and Dematal Corp. and Anormed’s Intention to Recommend to Its Shareholders the Acceptance of the Revised Offer to Be Made Thereunder. in Consideration of the Foregoing Agreement Between the Parties and Other Good and Valuable Consideration, the Sufficiency of Which Is Acknowledged: 1. Anormed Agrees to Pay Today the Amount of US$19.5 Million To, or as Directed By, the Parent; And